- 期刊
- OpenAccess
澳門非小細胞肺癌ALK免疫組化檢測
Immunohistochemical detection of ALK in non-small cell lung cancer in Macau
摘要
目的：檢測非小細胞肺癌（NSCLC）間變性淋巴瘤激酶（ALK）表達及與臨床病理特徵的關係，為臨床靶向治療方案的確定提供參考。方法：收集119例NSCLC，採用Ventana免疫組織化學方法檢測ALK。免疫組織化學結果與螢光原位雜交檢測進行比較。分析NSCLCALK表逹與患者臨床病理特徵的關係。結果：NSCLC組織中的ALK陽性率為9.24%（11/119）。免疫組織化學法與螢光原位雜交法檢測ALK的結果符合率為100%。ALK表逹與患者臨床特徵無關（P>0.05）。結論：免疫組織化學方法能有效檢測出NSCLCALK蛋白表逹，有幫助於臨床遴選出適合靶向藥物crizotinib治療的患者，而無需依賴NSCLC其它的臨床病理特征。
並列摘要
Objective: To detect protein expression of anaplastic lymphoma kinase (ALK) in non-small cell lung carcinoma (NSCLC), and explore its correlation with clinicopathologic features, so as to provide guidance for the administration of targeted therapy. Methods: Total 119 cases of NSCLC were collected from Kiang Wu Hospital Macau. Protein expression of ALK was detected by using immunohistochemical method. Results of both ALK tests, FISH and immunohistochemistry were compared. The correlation between ALK expression and clinicopathologic features was analyzed. Results: Positive ALK was detected in 9.24% (11/119) NSCLC. The results between ALK, FISH and immunoreaction are concordant in 100% of detected cases. The protein expression of ALK is not correlated with clinical features (P>0.05). Conclusion: Using immunohistochemical method ALK can be effectively detected in NSCLC. The detection can aid in identifying patients eligible for treatment with crizotinib, irrespective of their clinicopathologic features.